Structure-activity relationships for substituted bis(acridine-4- carboxamides): A new class of anticancer agents

Journal of Medicinal Chemistry

Volumn 42, Issue 13, 1999, Pages 2383-2393

  Gamage, Swarna A ^a   Spicer, Julie A ^a   Atwell, Graham J ^a   Finlay, Graeme J ^a   Baguley, Bruce C ^a   Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; BISNAFIDE MESYLATE; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; GLYCOPROTEIN P; IMIDACRINE; LU 79553; MITONAFIDE; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; UNCLASSIFIED DRUG; WMC 26;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN MCF 7; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DNA BINDING; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

ACRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; MICE; MUTATION; NEOPLASM TRANSPLANTATION; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0033168506     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980687m     Document Type: Article

References (38)

1. Le Pecq, J.-B.; Dat-Xuong, N.; Gosse, C.; Paoletti, C. A new antitumoral agent: 9-hydroxyellipticine. Possibility of a rational design of anticancerous drugs in the series of DNA intercalating drugs. Proc. Natl. Acad. Sci. U.S.A. 1974, 71, 5078-5082.
2. Baguley, B. C.; Denny, W. A.; Atwell, G. J.; Cain, B. F. Potential Antitumor Agents. Part 35. Quantitative relationships between antitumor (L1210) potency and DNA binding for 4′-(9-acridinylamino)methanesulfon-m-anisidide analogues. J. Med. Chem. 1981, 24, 520-525.
3. Hartley, J. A.; Reszka, K.; Zuo, E. T.; Wilson, W. D.; Morgan, A. R.; Lown, J. W. Characteristics of the interaction of anthrapyrazole anticancer agents with deoxyribonucleic acids: structural requirements for DNA binding, intercalation and photosensitization. Mol. Pharmacol. 1988, 33, 265-271.
4. Denny, W. A. DNA-Intercalating agents as antitumour drugs: prospects for future design. Anti-Cancer Drug Des. 1989, 4, 241-263.
5. Esnault, C.; Roques, P. B.; Jacquemin-Sablon, A.; Le Pecq, J.-B. Effects of new antitumor bifunctional intercalators derived from 7H-pyridocarbazole on sensitive and resistant L110 cell lines. Cancer Res. 1984, 44, 4355-4360.
6. Denny, W. A.; Atwell, G. J.; Baguley, B. C.; Wakelin, L. P. G. Potential Antitumor Agents. Part 44. Synthesis and antitumor activity of new classes of diacridines. The importance of linker chain rigidity for DNA binding kinetics and biological activity. J. Med. Chem. 1985, 28, 1568-1574.
7. Wakelin, L. P. G. Polyfunctional DNA intercalating agents. Med. Res. Rev. 1986, 6, 276-340.
8. Goldin, A.; Vendetti, M. M.; McDonald, J. S.; Muggia, F. M.; Henney, J. E.; DeVita, V. T. Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute. Eur. J. Cancer 1981, 17, 129-142.
9. Schepartz, S.; Venditti, J. M.; Plowman, J.; Wolpert, M. K. Report on the Program of the Division of Cancer Treatment; National Cancer Institute: Bethesda, MD, 1981.
10. Segal-Bendirjian, E.; Coulaud, D.; Roques, B. P.; Le Pecq, J.-B. Selective loss of mitochondrial DNA after treatment of cells with ditercalinium (NSC 335153), an antitumor bis-intercalating agent. Cancer Res. 1988, 48, 4982-4992.
11. Muss, H. B.; Blessing, J. A.; Eddy, G. L.; McGehee, R. Echinomycin (NSC-526417) in Recurrent and metastatic squamous cell carcinoma of the cervix - A Phase II trial of the Gynecologic Oncology Group (GOG). Invest. New Drugs 1992, 10, 25-26.
12. Wadler, S.; Tenteromano, L.; Cazenave, L.; Sparano, J. A.; Greenwald, E. S.; Rozenblit, A.; Kaleya, R.; Wiernik, P. H. Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer. Cancer Chemother. Pharmacol. 1994, 34, 266-269.
13. Diaz-Rubio, E.; Martin, M.; Lopez-Vega, J. M.; Casado, A.; Benavides, A. Phase I study of mitonafide with a 3-day administration schedule: early interruption due to severe central nervous system toxicity. Invest. New Drugs 1994, 12, 277-281.
14. McRipley, R. J.; Burns-Horwitz, P. E.; Czerniak, P. M.; Diamond, R. J.; Diamond, M. A.; Miller, J. L. D.; Page, F. J.; Dexter, D. L.; Chen, S. F. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity. Cancer Res. 1994, 54, 159-164.
15. Houghton, P. J.; Cheshire, P. J.; Hallman, J. C.; Gross, J. L.; McRipley, R. J.; Sun, J. H.; Behrens, C. H.; Dexter, D. L.; Houghton, J. A. Evaluation of a novel bis-naphthalimide anticancer agent, DMP-840, against human xenografts derived from adult, juvenile, and pediatric cancers. Cancer Chemother. Pharmacol. 1994, 33, 265-272.
16. LoRusso, P.; Demchik, L.; Dan, M.; Polin, L.; Gross, J. L.; Corbett, T. H. Comparative efficacy of DMP 840 against mouse and human solid tumor models. Invest. New Drugs 1995, 13, 195-203. Robinson, C. P.; Robinson, K. A.; Castaner, J. Bisnafide mesylate. Antineoplastic DMP-840 (NSC D640430). Drugs Future 1996, 21, 239-244.
17. LoRusso, P.; Demchik, L.; Dan, M.; Polin, L.; Gross, J. L.; Corbett, T. H. Comparative efficacy of DMP 840 against mouse and human solid tumor models. Invest. New Drugs 1995, 13, 195-203. Robinson, C. P.; Robinson, K. A.; Castaner, J. Bisnafide mesylate. Antineoplastic DMP-840 (NSC D640430). Drugs Future 1996, 21, 239-244.
18. Brana, M. F.; Castellano, J. M.; Moran, M.; Perez de Vega, M. J.; Perron, D.; Conlon, D.; Bousquet, P. F.; Romerdahl, C. A.; Robinson, S. P. Bis-naphthalimides 3: Synthesis and antitumor activity of N,N′-bis[2-(1,8-naphthalimido)ethyl]alkane-diamines. Anti-Cancer Drug Des. 1996, 11, 297-309.
19. Dziegielewski, J.; Konopa, J. Interstrand cross-linking of DNA in tumor cells by a new group of antitumor imidazoacridinones. Proc. Am. Assoc. Cancer Res. 1996, 37, 410 (abstract 2800).
20. Cholody, W. M.; Hernandez, L.; Hassner, L.; Scuderio, D. A.; Djurickovic, D. B.; Michejda, C. J. Bisimidazoacridones and related compounds: new antineoplastic agents with high selectivity against colon tumours. J. Med. Chem. 1995, 38, 3043-3052.
21. Baguley, B. C.; Zhuang, L.; Marshall, E. M. Experimental solid tumour activity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. Cancer Chemother. Pharmacol. 1995, 36, 244-248.
22. Finlay, G. J.; Riou, J.-F.; Baguley, B. C. From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. Eur. J. Cancer 1996, 32A, 708-714.
23. Schneider, E.; Darkin, S. A.; Lawson, P. A.; Ching, L.-M.; Ralph, R. K.; Baguley, B. C. Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]-acridine-4-carboxamide: role of DNA topoisomerase II. Eur. J. Cancer Clin. Oncol. 1988, 24, 1783-1790.
24. Atwell, G. J.; Rewcastle, G. W.; Baguley, B. C.; Denny, W. A. Potential antitumor agents. 50. In vivo solid tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J. Med. Chem. 1987, 30, 664-669.
25. Finlay, G. J.; Marshall, E. S.; Matthews, J. H. L.; Paull, K. D.; Baguley, B. C. In vitro assessment of N-[2-(dimethylamino)ethyl]-acridine-4-carboxamide (DACA), a DNA intercalating antitumor drug with reduced sensitivity to multidrug resistance. Cancer Chemother. Pharmacol. 1993, 31, 401-406.
26. Finlay, G. J.; Baguley, B. C.; Snow, K.; Judd, W. Multiple patterns of resistance of human leukemia cell sublines to analogues of amsacrine. J. Natl. Cancer Inst. 1990, 82, 662-667.
27. Spicer, J. A.; Gamage, S. A.; Atwell, G. J.; Finlay, G. J.; Baguley, B. C.; Denny, W. A. Dimeric analogues of noncationic tricyclic aromatic carboxamides are a new class of cytotoxic agents. Anti-Cancer Drug Des., submitted.
28. Gamage, S. A.; Spicer, J. A.; Rewcastle, G. W.; Denny, W. A. A new synthesis of substituted acridine-4-carboxylic acids and the anticancer drug N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA). Tetrahedron Lett. 1997, 38, 699-702.
29. Spicer, J. A.; Gamage, S. A.; Atwell, G. J.; Finlay, G. J.; Baguley, B. C.; Denny, W. A. Structure-activity relationships for acridine-substituted analogues of the mixed topo I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA). J. Med. Chem. 1997, 40, 1919-1929.
30. Finlay, G. J.; Holdaway, K. M.; Baguley, B. C. Comparison of the effects of genistein and amsacrine on leukemia cell proliferation. Oncol. Res. 1994, 6, 33-37.
31. Wilkoff, L. J.; Dulmadge, E.; Chopra, D. P. Viability of cultured Lewis lung cell populations exposed to β-retinoic acid (40753). Proc. Soc. Exp. Biol. Med. 1980, 163, 233-236.
32. Denny, W. A.; Atwell, G. J.; Cain, B. F.; Leo, A.; Panthananickal, A.; Hansch, C. Potential Antitumor Agents. Part 36. Quantitative relationships between antitumor potency, toxicity and structure for the general class of 9-anilinoacridine antitumor agents. J. Med. Chem. 1982, 25, 276-316.
33. Spicer, J. A.; Finlay, G. J.; Baguley, B. C.; Velea, L.; Graves, D. E.; Denny, W. A. 5,7-Disubstituted analogues of the mixed topoisomerase I/II poison N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA). Anti-Cancer Drug Des., submitted.
34. Robertson, I. G. C.; Palmer, B. D.; Officer, M.; Siegers, D. J.; Paxton, J. W.; Shaw, G. J. Cytosol mediated metabolism of the experimental antitumor agent acridine carboxamide to the 9-acridone derivative. Biochem. Pharmacol. 1991, 42, 1879-1884.
35. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campbell, H.; Mayo, J.; Boyd, M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 1991, 83, 757-766.
36. Bridewell, D. J. A.; Finlay, G. J.; Baguley, B. C. Differential actions of aclarubicin and doxorubicin: the role of topoisomerase I. Oncol. Res. 1997, 9, 535-542.
37. Marshall, E. S.; Finlay, G. J.; Matthews, J. H. L.; Shaw, J. H. F.; Nixon, J.; Baguley, B. C. Microculture-based chemosensitivity testing: a feasibility study comparing freshly explanted melanoma cells with human melanoma cell lines. J. Natl. Cancer Inst. 1992, 84, 340-345.
38. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82, 1107-1112.